A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
Advances in Pharmacology and Pharmacy · 2014
DOI: 10.13189/app.2014.020101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacology and Pharmacy, 2014. Verfasst von Katie L Axford und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Axford, K. L., & Shiltz, D. L. (2014). A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia. Advances in Pharmacology and Pharmacy. https://doi.org/10.13189/app.2014.020101
Vancouver
Axford KL, Shiltz DL. A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia. Advances in Pharmacology and Pharmacy. 2014. doi:10.13189/app.2014.020101
BibTeX
@article{Axford2014,
author = {Axford, Katie L and Shiltz, Dane L},
title = {A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia},
journal = {Advances in Pharmacology and Pharmacy},
year = {2014},
doi = {10.13189/app.2014.020101}
}
EUVIMED